Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Cipla to launch respiratory inhaler Synchrobreathe for asthma

Synchrobreathe, a breath-actuated inhaler (BAI) with a dose counter, helps in the management of Obstructive Airway Disease (OAD)

BS B2B Bureau  |  Mumbai 

Cipla will soon launch an innovative inhaler, called Synchrobreathe, which will bring important benefits for physicians, patients and healthcare providers on managing Obstructive Airway Disease (OAD). Synchrobreathe is a novel, breath-actuated inhaler (BAI) with a dose counter.
 
Frank Pieters, global head of respiratory for Cipla, said, “Simple and intuitive, Synchrobreathe is an innovation in managing respiratory disease. Synchrobreathe is attractive for patients as the inhaler is easy to use effectively. Equally importantly, Synchrobreathe will help cut the time healthcare providers need to spend to train patients in correct inhaler use. With this simple inhaler, the healthcare professional knows the patient will be able to use it easily and get the full benefit from every dose.”
 
Cipla made a presentation on Synchrobreathe at the South Africa Thoracic Society (SATS) conference in Cape Town (7-10 August 2015) where around 200 healthcare providers, pulmonologists, thoracic surgeons and other specialists present.
 
Paul Miller, CEO Cipla Medpro, South Africa added, “South Africa has amongst the highest asthma mortality rates in the world. As a leading company in the area of respiratory health in South Africa, we are proud to announce the development of this innovation for the first time to the medical community at the SATS congress. Synchrobreathe will definitely make patients’ lives easier in managing their Obstructive Airway Disease. Synchrobreathe is expected to reach the market in the current year.”

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, August 11 2015. 14:38 IST
RECOMMENDED FOR YOU

Cipla to launch respiratory inhaler Synchrobreathe for asthma

Synchrobreathe, a breath-actuated inhaler (BAI) with a dose counter, helps in the management of Obstructive Airway Disease (OAD)

Synchrobreathe, a breath-actuated inhaler (BAI) with a dose counter, helps in the management of Obstructive Airway Disease (OAD) Cipla will soon launch an innovative inhaler, called Synchrobreathe, which will bring important benefits for physicians, patients and healthcare providers on managing Obstructive Airway Disease (OAD). Synchrobreathe is a novel, breath-actuated inhaler (BAI) with a dose counter.
 
Frank Pieters, global head of respiratory for Cipla, said, “Simple and intuitive, Synchrobreathe is an innovation in managing respiratory disease. Synchrobreathe is attractive for patients as the inhaler is easy to use effectively. Equally importantly, Synchrobreathe will help cut the time healthcare providers need to spend to train patients in correct inhaler use. With this simple inhaler, the healthcare professional knows the patient will be able to use it easily and get the full benefit from every dose.”
 
Cipla made a presentation on Synchrobreathe at the South Africa Thoracic Society (SATS) conference in Cape Town (7-10 August 2015) where around 200 healthcare providers, pulmonologists, thoracic surgeons and other specialists present.
 
Paul Miller, CEO Cipla Medpro, South Africa added, “South Africa has amongst the highest asthma mortality rates in the world. As a leading company in the area of respiratory health in South Africa, we are proud to announce the development of this innovation for the first time to the medical community at the SATS congress. Synchrobreathe will definitely make patients’ lives easier in managing their Obstructive Airway Disease. Synchrobreathe is expected to reach the market in the current year.”
image
Business Standard
177 22

Cipla to launch respiratory inhaler Synchrobreathe for asthma

Synchrobreathe, a breath-actuated inhaler (BAI) with a dose counter, helps in the management of Obstructive Airway Disease (OAD)

Cipla will soon launch an innovative inhaler, called Synchrobreathe, which will bring important benefits for physicians, patients and healthcare providers on managing Obstructive Airway Disease (OAD). Synchrobreathe is a novel, breath-actuated inhaler (BAI) with a dose counter.
 
Frank Pieters, global head of respiratory for Cipla, said, “Simple and intuitive, Synchrobreathe is an innovation in managing respiratory disease. Synchrobreathe is attractive for patients as the inhaler is easy to use effectively. Equally importantly, Synchrobreathe will help cut the time healthcare providers need to spend to train patients in correct inhaler use. With this simple inhaler, the healthcare professional knows the patient will be able to use it easily and get the full benefit from every dose.”
 
Cipla made a presentation on Synchrobreathe at the South Africa Thoracic Society (SATS) conference in Cape Town (7-10 August 2015) where around 200 healthcare providers, pulmonologists, thoracic surgeons and other specialists present.
 
Paul Miller, CEO Cipla Medpro, South Africa added, “South Africa has amongst the highest asthma mortality rates in the world. As a leading company in the area of respiratory health in South Africa, we are proud to announce the development of this innovation for the first time to the medical community at the SATS congress. Synchrobreathe will definitely make patients’ lives easier in managing their Obstructive Airway Disease. Synchrobreathe is expected to reach the market in the current year.”

image
Business Standard
177 22